Industry
Biotechnology
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 10:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 9:39 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
April 16, 2024 | 12:42 pm
Portfolio Pulse from Benzinga Newsdesk
April 15, 2024 | 2:33 pm
Portfolio Pulse from Benzinga Neuro
February 29, 2024 | 4:02 am
Portfolio Pulse from Benzinga Neuro
February 28, 2024 | 3:35 am
Portfolio Pulse from Benzinga Neuro
February 27, 2024 | 3:45 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.